EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label study to evaluate the dose of Orenitram® (treprostinil)
Extended Release Tablets achieved at 16 weeks after a short-term course of Remodulin®
(treprostinil) Injection in subjects with pulmonary arterial hypertension (PAH).